Tags

Type your tag names separated by a space and hit enter

Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 diabetes with nephropathy: a longitudinal randomized clinical trial.
Diabetes Care. 2008 Apr; 31(4):648-54.DC

Abstract

OBJECTIVE

Several short-term trials on the effect of soy consumption on cardiovascular risks are available, but little evidence exists regarding the impact of long-term soy protein consumption among type 2 diabetic patients with nephropathy. To determine the effects of long-term soy consumption on cardiovascular risks, we measured C-reactive protein (CRP) and kidney function indexes among type 2 diabetic patients with nephropathy.

RESEARCH DESIGN AND METHODS

This longitudinal randomized clinical trial was conducted among 41 type 2 diabetic patients with nephropathy (18 men and 23 women). Twenty patients in the soy protein group consumed a diet containing 0.8 g protein/kg body weight (35% animal proteins, 35% textured soy protein, and 30% vegetable proteins) and 21 patients in the control group consumed a similar diet containing 70% animal proteins and 30% vegetable proteins for 4 years.

RESULTS

Soy protein consumption significantly affected cardiovascular risks such as fasting plasma glucose (mean change in the soy protein versus control groups: -18 +/- 3 vs. 11 +/- 2 mg/dl; P = 0.03), total cholesterol (-23 +/- 5 vs. 10 +/- 3 mg/dl; P = 0.01), LDL cholesterol (-20 +/- 5 vs. 6 +/- 2 mg/dl; P = 0.01), and serum triglyceride (-24 +/- 6 vs. -5 +/- 2 mg/dl; P = 0.01) concentrations. Serum CRP levels were significantly decreased by soy protein intake compared with those in the control group (1.31 +/- 0.6 vs. 0.33 +/- 0.1 mg/l; P = 0.02). Significant improvements were also seen in proteinuria (-0.15 +/- 0.03 vs. 0.02 +/- 0.01 g/day; P = 0.001) and urinary creatinine (-1.5 +/- 0.9 vs. 0.6 +/- 0.3 mg/dl, P = 0.01) by consumption of soy protein.

CONCLUSIONS

Longitudinal soy protein consumption significantly affected cardiovascular risk factors and kidney-related biomarkers among type 2 diabetic patients with nephropathy.

Authors+Show Affiliations

Department of Nutrition, School of Public Health, Isfahan University of Medical Sciences, Isfahan, P.O. Box 81745, Iran. azadbakht@hlth.mui.ac.irNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18184902

Citation

Azadbakht, Leila, et al. "Soy Protein Intake, Cardiorenal Indices, and C-reactive Protein in Type 2 Diabetes With Nephropathy: a Longitudinal Randomized Clinical Trial." Diabetes Care, vol. 31, no. 4, 2008, pp. 648-54.
Azadbakht L, Atabak S, Esmaillzadeh A. Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 diabetes with nephropathy: a longitudinal randomized clinical trial. Diabetes Care. 2008;31(4):648-54.
Azadbakht, L., Atabak, S., & Esmaillzadeh, A. (2008). Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 diabetes with nephropathy: a longitudinal randomized clinical trial. Diabetes Care, 31(4), 648-54. https://doi.org/10.2337/dc07-2065
Azadbakht L, Atabak S, Esmaillzadeh A. Soy Protein Intake, Cardiorenal Indices, and C-reactive Protein in Type 2 Diabetes With Nephropathy: a Longitudinal Randomized Clinical Trial. Diabetes Care. 2008;31(4):648-54. PubMed PMID: 18184902.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 diabetes with nephropathy: a longitudinal randomized clinical trial. AU - Azadbakht,Leila, AU - Atabak,Shahnaz, AU - Esmaillzadeh,Ahmad, Y1 - 2008/01/09/ PY - 2008/1/11/pubmed PY - 2008/8/7/medline PY - 2008/1/11/entrez SP - 648 EP - 54 JF - Diabetes care JO - Diabetes Care VL - 31 IS - 4 N2 - OBJECTIVE: Several short-term trials on the effect of soy consumption on cardiovascular risks are available, but little evidence exists regarding the impact of long-term soy protein consumption among type 2 diabetic patients with nephropathy. To determine the effects of long-term soy consumption on cardiovascular risks, we measured C-reactive protein (CRP) and kidney function indexes among type 2 diabetic patients with nephropathy. RESEARCH DESIGN AND METHODS: This longitudinal randomized clinical trial was conducted among 41 type 2 diabetic patients with nephropathy (18 men and 23 women). Twenty patients in the soy protein group consumed a diet containing 0.8 g protein/kg body weight (35% animal proteins, 35% textured soy protein, and 30% vegetable proteins) and 21 patients in the control group consumed a similar diet containing 70% animal proteins and 30% vegetable proteins for 4 years. RESULTS: Soy protein consumption significantly affected cardiovascular risks such as fasting plasma glucose (mean change in the soy protein versus control groups: -18 +/- 3 vs. 11 +/- 2 mg/dl; P = 0.03), total cholesterol (-23 +/- 5 vs. 10 +/- 3 mg/dl; P = 0.01), LDL cholesterol (-20 +/- 5 vs. 6 +/- 2 mg/dl; P = 0.01), and serum triglyceride (-24 +/- 6 vs. -5 +/- 2 mg/dl; P = 0.01) concentrations. Serum CRP levels were significantly decreased by soy protein intake compared with those in the control group (1.31 +/- 0.6 vs. 0.33 +/- 0.1 mg/l; P = 0.02). Significant improvements were also seen in proteinuria (-0.15 +/- 0.03 vs. 0.02 +/- 0.01 g/day; P = 0.001) and urinary creatinine (-1.5 +/- 0.9 vs. 0.6 +/- 0.3 mg/dl, P = 0.01) by consumption of soy protein. CONCLUSIONS: Longitudinal soy protein consumption significantly affected cardiovascular risk factors and kidney-related biomarkers among type 2 diabetic patients with nephropathy. SN - 1935-5548 UR - https://www.unboundmedicine.com/medline/citation/18184902/Soy_protein_intake_cardiorenal_indices_and_C_reactive_protein_in_type_2_diabetes_with_nephropathy:_a_longitudinal_randomized_clinical_trial_ L2 - http://care.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=18184902 DB - PRIME DP - Unbound Medicine ER -